-
Key Takeaways in mCSPC: Combination Therapy and Germline Testing Is the New Standard of Care
23 Jul 2025 22:11 GMT
Panelists discuss how androgen deprivation therapy (ADT) monotherapy is no longer … cancer (mCSPC), emphasizing that combination therapy with androgen receptor (AR) pathway inhibitors …
-
ARCHES: 5-Year Follow-up Overall Survival (OS) Analysis of Enzalutamide (ENZA) Plus Androgen-Deprivation Therapy (ADT) in Patients (pts) With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
24 Jun 2025 21:08 GMT
… trial showing that enzalutamide plus androgen-deprivation therapy significantly prolonged overall survival versus …
-
CaRe Prostate Study of INKmune in Metastatic CRPC Hits Primary, Secondary End Points
04 Aug 2025 19:46 GMT
… disease progression following treatment with androgen deprivation therapy (ADT) and at least 1 … androgen receptor inhibitor, have not received …
-
Consensus Guidelines Needed to Further Optimize PARP Inhibition, Molecular Imaging, and ARPI Use in Prostate Cancer Management
04 Aug 2025 13:51 GMT
… imaging, and earlier use of androgen receptor pathway inhibitors (ARPIs), … of patients are still receiving therapy with androgen deprivation therapy [ADT] alone. There… hormonal agents, including CYP11 inhibitors. Androgen receptor degraders are also being …
-
Patients’ Preferences for Attributes of Oral vs Injectable Androgen Deprivation Therapy in Prostate Cancer: A Discrete Choice Experiment
09 May 2025 10:21 GMT
… relative importance estimates.
Abbreviations: ADT, androgen deprivation therapy; RI, relative importance.
Notes: … Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer …
-
Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial.
07 May 2025 17:11 GMT
… acid (ZA) in combination with androgen deprivation therapy (ADT) has never proved additional … cancer bone metastases to systemic therapy.
Prostate cancer and prostatic diseases …
-
AUA 2025: New Data from Post-Hoc Analyses Shared on Ultra-Low Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Hormone-Sensitive Prostate Cancer Receiving NUBEQA® (darolutamide) plus Androgen Deprivation Therapy (ADT)
29 Apr 2025 12:28 GMT
… receiving NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) were more likely … will metastasize or spread, androgen deprivation therapy (ADT) is the … Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic …
-
AUA 2025: Testosterone Recovery Profiles after Cessation of Androgen Deprivation Therapy for Prostate Cancer: A Meta-Analysis of Prospective Trials
29 Apr 2025 01:48 GMT
… recovery profiles after cessation of androgen deprivation therapy (ADT) in prostate cancer … outcomes following cessation of hormone therapy, stratified by drug class… outcomes following discontinuation of hormone therapy and patient counseling for guiding …
-
Real-world analyses of major adverse cardiovascular events and mortality risk after androgen deprivation therapy initiation in black vs. white prostate cancer patients.
22 Apr 2025 16:05 GMT
… cancer(PCa) patients treated with androgen deprivation therapy(ADT) may experience major adverse …
-
The Benefit of Short-Term Androgen Deprivation Therapy with Radiotherapy for Intermediate-Risk Prostate Cancer - Beyond the Abstract
14 Apr 2025 21:53 GMT
Historically, short-term androgen deprivation therapy (ST-ADT) has been considered … . In these trials, the radiation therapy was delivered with techniques, and …
About
© 1995-2025